scholarly journals Immunization Stress-Related Responses: Mitigating Patient Fears and Associated Side Effects Amidst a Global Vaccination Effort

2022 ◽  
pp. 36-41
Author(s):  
Michael Mast ◽  
Yihan Li
Keyword(s):  
United States ◽  
Side Effects ◽  
Adverse Events ◽  
The United States ◽  
Mass Vaccination ◽  
Vaccine Hesitancy ◽  
Substantial Role

The event of receiving a vaccine can lead to feelings of stress and anxiety for many patients and may present as adverse events. With coronavirus disease 2019 (COVID-19) mass vaccination efforts, adverse events following immunization, including immunization stress-related reactions (ISRR), have subsequently increased. Traditionally rare, but increasingly common, cluster events have also become a concern. Demonstrated in recent publications by Hause et al. concerning Janssen (Johnson & Johnson) COVID-19 vaccine clinics, these adverse events can lead to personal apprehension towards receiving vaccines, as well as public distrust towards the immunization process. To combat ISRRs, mass vaccination clinics across the United States must create administration protocols to mitigate these responses. Anticipation and swift management can play a substantial role in minimizing frequency and severity of these reactions and prevent future vaccine hesitancy.

scholarly journals SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey

2021 ◽  
pp. ASN.2021010104
Author(s):  
Pablo Garcia ◽  
Maria E. Montez-Rath ◽  
Heather Moore ◽  
Johnie Flotte ◽  
Chris Fults ◽  
...  
Keyword(s):  
United States ◽  
Native American ◽  
Side Effects ◽  
The United States ◽  
Vaccine Uptake ◽  
Vaccine Hesitancy ◽  
Vaccine Acceptability ◽  
Increased Risk ◽  
Hispanic White ◽  
White Patients

BackgroundPatients on dialysis are at increased risk for COVID-19–related complications. However, a substantial fraction of patients on dialysis belong to groups more likely to be hesitant about vaccination.MethodsWith the goal of identifying strategies to increase COVID-19 vaccine uptake among patients on hemodialysis, we conducted a nationwide vaccine acceptability survey, partnering with a dialysis network to distribute an anonymized English and Spanish language online survey in 150 randomly selected facilities in the United States. We used logistic regression to evaluate characteristics of vaccine-hesitant persons.ResultsA total of 1515 (14% of eligible) patients responded; 20% of all responders, 29% of patients aged 18–44 years, and 29% of Black responders reported being hesitant to seek the COVID-19 vaccine, even if the vaccine was considered safe for the general population. Odds of vaccine hesitancy were higher among patients aged 18–44 years versus those 45–64 years (odds ratio [OR], 1.5; 95% confidence interval [95% CI], 1.0 to 2.3), Black patients versus non-Hispanic White patients (OR, 1.9; 95% CI, 1.3 to 2.7), Native Americans or Pacific Islanders versus non-Hispanic White patients (OR, 2.0; 95% CI, 1.1 to 3.7), and women versus men (OR, 1.6; 95% CI, 1.2 to 2.0). About half (53%) of patients who were vaccine hesitant expressed concerns about side effects. Responders’ main information sources about COVID-19 vaccines were television news and dialysis staff (68% and 38%, respectively).ConclusionsA substantial proportion of patients receiving in-center hemodialysis in the United States are hesitant about seeking COVID-19 vaccination. Facilitating uptake requires outreach to younger patients, women, and Black, Native American, or Pacific Islander patients, and addressing concerns about side effects.

scholarly journals Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Egilius L. H. Spierings ◽  
Mikko Kärppä ◽  
Xiaoping Ning ◽  
Joshua M. Cohen ◽  
Verena Ramirez Campos ◽  
...  
Keyword(s):  
United States ◽  
Czech Republic ◽  
Adverse Events ◽  
Least Squares ◽  
The United States ◽  
Inadequate Response ◽  
Double Blind ◽  
Monthly Average ◽  
Preventive Medication ◽  
Subgroup Analyses

Abstract Background The FOCUS study evaluated the efficacy of migraine preventive medications across different countries within the same patient population, particularly for patients with difficult-to-treat migraine. These prespecified subgroup analyses evaluated efficacy by country in the FOCUS study of fremanezumab in adults with episodic migraine or chronic migraine and documented inadequate response to 2 to 4 migraine preventive medication classes. Methods Overall, 838 participants were enrolled in the FOCUS study, a randomized, double-blind, placebo-controlled, parallel-group, phase 3b study performed at 104 sites. For 12 weeks of double-blind treatment, patients were randomized (1:1:1) to quarterly fremanezumab, monthly fremanezumab, or matched placebo. The primary efficacy endpoint was the mean change from baseline in monthly average migraine days over 12 weeks of double-blind treatment, evaluated by country in these subgroup analyses. Results Of 14 countries contributing data, the Czech Republic (n = 188/838; 22%), the United States (n = 120/838; 14%), and Finland (n = 85/838; 10%) enrolled the most patients. Changes from baseline in monthly average migraine days over 12 weeks were significantly greater with fremanezumab versus placebo for patients in these countries: Czech Republic (least-squares mean difference versus placebo [95% confidence interval]: quarterly fremanezumab, − 1.9 [− 3.25, − 0.47]; P = 0.009; monthly fremanezumab, − 3.0 [− 4.39, − 1.59]; P < 0.001), the United States (quarterly fremanezumab, − 3.7 [− 5.77, − 1.58]; P < 0.001; monthly fremanezumab, − 4.2 [− 6.23, − 2.13]; P < 0.001), and Finland (quarterly fremanezumab, − 3.0 [− 5.32, − 0.63]; P = 0.014; monthly fremanezumab, − 3.9 [− 6.27, − 1.44]; P = 0.002). Results were comparable for the remaining 9 countries, with the least-squares mean difference versus placebo ranging from – 5.6 to – 2.4 with quarterly fremanezumab and from − 5.3 to − 1.5 with monthly fremanezumab. Incidences of serious adverse events and adverse events leading to discontinuation were low and comparable across countries and treatment groups. Conclusions Monthly and quarterly fremanezumab significantly reduced the monthly average number of migraine days versus placebo regardless of country and continent (North America versus Europe) in migraine patients with documented inadequate response to 2 to 4 migraine preventive medication classes. Trial registration ClinicalTrials.gov Identifier: NCT03308968.

VACCINE HESITANCY TO VACCINE DESPERATION! EXPERIENCES FROM 2 VACCINATION CENTERS IN MUMBAI.

2021 ◽  
pp. 43-45
Author(s):  
Reena J. Wani ◽  
Sanjay Panchal ◽  
Kinjal Chauhan ◽  
Varun J. Wani ◽  
Priya H. Manihar ◽  
...  
Keyword(s):  
Side Effects ◽  
Adverse Events ◽  
Hand Hygiene ◽  
Special Reference ◽  
Vaccine Hesitancy ◽  
Long Term Effects ◽  
Social Distancing ◽  
Roll Out ◽  
Available Resources

Since the beginning of the COVID-19 Pandemic and Lockdown on March 2020 till date, measures like hand hygiene, social distancing and testing have worked only partially to contain the cases and deaths. Cooper and Nair Hospitals were amongst the nodal centres identied in January 2021 to launch the Nationwide Vaccination drive in Mumbai. Aim: To highlight the pattern of vaccination roll-out, procedures in various phases and discuss concerns, challenges and effect on our workforce and workplan. Methodology: We reviewed the patterns, uptake of vaccine, procedures and problems faced by our vaccination centres from January 15 till April 30 (4 months). We also looked into adverse events following immunization (AEFI) reported. th th Results: Over 68,000 vaccine doses have been administrated in Cooper alone by April end, and issues were analysed in detail with special reference to logistics & challenges. AEFI were very few. We found that initially anxiety about side effects, concerns about choice of vaccine and long-term effects were the major impediments to vaccination. Later on, the demand exceeded the supply. Conclusion: Although vaccination is not the nal answer, it is an important tool to improve our response to the pandemic. Reviewing, restructuring available resources is essential in pandemic situations. Proper planning, counselling and choice in the way forward in this crisis.

Serious Adverse Events Reported with Dietary Supplement Use in the United States: A 2.5 Year Experience

2018 ◽  
Vol 17 (2) ◽  
pp. 227-248 ◽  
Author(s):  
Stephen M. Schmitz ◽  
Hector L. Lopez ◽  
Douglas Mackay ◽  
Haiuyen Nguyen ◽  
Paula E. Miller
Keyword(s):  
United States ◽  
Adverse Events ◽  
Dietary Supplement ◽  
The United States ◽  
Serious Adverse Events ◽  
Supplement Use ◽  
Dietary Supplement Use

scholarly journals Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States

2020 ◽  
Vol 3 (12) ◽  
pp. e2031647 ◽  
Author(s):  
Katsiaryna Bykov ◽  
Brian T. Bateman ◽  
Jessica M. Franklin ◽  
Seanna M. Vine ◽  
Elisabetta Patorno
Keyword(s):  
United States ◽  
Adverse Events ◽  
The United States ◽  
Surgical Patients

scholarly journals The comparison of vaccine hesitancy of COVID-19 vaccination in China and the United States

2021 ◽  
Author(s):  
Taoran Liu ◽  
Zonglin He ◽  
Jian Huang ◽  
Ni Yan ◽  
Qian Chen ◽  
...  
Keyword(s):  
United States ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Discrete Choice ◽  
Choice Experiments ◽  
The United States ◽  
Discrete Choice Experiments ◽  
Vaccine Hesitancy ◽  
The Us ◽  
The Cost

AbstractObjectivesTo investigate the differences in vaccine hesitancy and preference of the currently available COVID-19 vaccines between two countries, viz. China and the United States (US).MethodA cross-national survey was conducted in both China and the US, and discrete choice experiments as well as Likert scales were utilized to assess vaccine preference and the underlying factors contributing to the vaccination acceptance. A propensity score matching (PSM) was performed to enable a direct comparison between the two countries.ResultsA total of 9,077 (5,375 and 3,702, respectively, from China and the US) respondents have completed the survey. After propensity score matching, over 82.0% respondents from China positively accept the COVID-19 vaccination, while 72.2% respondents form the US positively accept it. Specifically, only 31.9% of Chinese respondents were recommended by a doctor to have COVID-19 vaccination, while more than half of the US respondents were recommended by a doctor (50.2%), local health board (59.4%), or friends and families (64.8%). The discrete choice experiments revealed that respondents from the US attached the greatest importance to the efficacy of COVID-19 vaccines (44.41%), followed by the cost of vaccination (29.57%), whereas those from China held a different viewpoint that the cost of vaccination covers the largest proportion in their trade-off (30.66%), and efficacy ranked as the second most important attribute (26.34%). Also, respondents from China tend to concerned much more about the adverse effect of vaccination (19.68% vs 6.12%) and have lower perceived severity of being infected with COVID-19.ConclusionWhile the overall acceptance and hesitancy of COVID-19 vaccination in both countries are high, underpinned distinctions between countries are observed. Owing to the differences in COVID-19 incidence rates, cultural backgrounds, and the availability of specific COVID-19 vaccines in two countries, the vaccine rollout strategies should be nation-dependent.

Understanding and Improving U.S. Financial Sanctions

2017 ◽  
Author(s):  
Jennifer M. Harris ◽  
Robert B. Kahn
Keyword(s):  
United States ◽  
Foreign Policy ◽  
Side Effects ◽  
The United States ◽  
Policy Tools ◽  
The Past

This chapter uses the Iran and Russia cases to understand how modern U.S. financial sanctions operate (including how they interact with traditional tools of foreign policy) and how to better incorporate them into the United States’ standing arsenal of foreign policy tools. It does so by considering three broad sets of questions: First, how has the use of financial sanctions evolved over the past fifteen years? Second, what are the main ways in which financial sanctions impose costs on sanctioned countries? Finally, how should U.S. policymakers alter the use of financial sanctions to maximize their impact, sustain their strength, and minimize problematic side effects?

Using an HIV Disclosure Model to Slow the Spread of COVID-19

2021 ◽  
pp. 152483992110350
Author(s):  
Antonio J. Gardner ◽  
Ashley White Jones
Keyword(s):  
United States ◽  
Primary Prevention ◽  
The United States ◽  
Hiv Disclosure ◽  
Vaccine Hesitancy ◽  
Community Settings ◽  
Black African ◽  
Disclosure Decisions ◽  
Prevention Method ◽  
Black Populations

Black/African American populations in the United States are disproportionately affected by the COVID-19 pandemic, and there is evidence suggesting that vaccine hesitancy is a concern among this group. As an alternative to the primary prevention method of vaccination, the tertiary method of disclosing one’s COVID-19 status after contracting the virus is of utmost importance in reducing the spread of the virus. Recommendations to inform disclosure decisions based on an HIV disclosure model can be applied to COVID-19-positive Black populations in clinical and community settings to reduce the spread of the virus among this population.

Uncertainties in Vaccination

Uncertainty ◽  
2019 ◽  
pp. 93-106
Author(s):  
Kostas Kampourakis ◽  
Kevin McCain
Keyword(s):  
United States ◽  
Side Effects ◽  
The United States ◽  
Efficacy And Safety ◽  
Real Possibility ◽  
The Past

Whereas vaccines have helped save millions of lives over the past several decades, today there is a significant anti-vaccination (anti-vaxx) movement, especially in the United States, that questions their safety. The problem is that these anti-vaxx arguments focus on rare cases of side effects or—even worse—on unfounded connections between the administration of vaccines and particular conditions such as autism. Such reactions make people overlook the fact that several diseases that in the past killed millions of people have been completely or almost completely eradicated thanks to vaccines. Even though vaccine side effects are a real possibility, one has to weigh the risk of facing those (which is very low and arise in relatively rare cases) against the hundreds or thousands of children who, thanks to the vaccine, will avoid hospitalization or even death. Uncertainties always exist, and we cannot be absolutely certain about the efficacy and safety of any vaccine. But for many of them, there is solid evidence that the problems are rare, and certainly the affected individuals are a lot fewer than those who might suffer and even die from the disease.

Sign in / Sign up

Export Citation Format

Share Document